Boehringer Ingelheim, the German pharmaceutical giant, officially launched the Pulmonary Fibrosis Care Initiative late last...
Boehringer Ingelheim, the privately held German pharmaceutical leader, has launched a new Artificial Intelligence (AI)...
Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Boehringer Ingelheim (BI) have announced a strategic clinical...
The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs...
Boehringer Ingelheim and BioNTech SE (NASDAQ: BNTX) have announced a clinical collaboration to evaluate a...
Boehringer Ingelheim (BI) announced a licensing agreement with Sitryx Therapeutics, obtaining exclusive global rights to...
Boehringer Ingelheim and Simcere Pharmaceutical Group (HKG: 2096) announced a licensing and collaboration agreement to...
Boehringer Ingelheim and Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced a strategic clinical collaboration to evaluate a...
Boehringer Ingelheim announced at the 8th China International Import Expo (CIIE) that it has signed...
Boehringer Ingelheim announced a licensing deal to acquire exclusive worldwide rights to a promising first‑in‑class...
Boehringer Ingelheim announced that its oral selective phosphodiesterase‑4B (PDE4B) inhibitor Nerandomilast (JASCAYD®) has received formal...
Boehringer Ingelheim today disclosed a worldwide collaboration and licensing agreement with AimedBio to develop a...
Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved...
In a joint announcement, Boehringer Ingelheim (BI) and Sino Biopharmaceutical Limited (HKG: 1177) confirmed that the...
German pharmaceutical giant Boehringer Ingelheim (BI) announced that its HERNEXEOS (zongertinib tablets) has received accelerated...
German pharmaceutical giant Boehringer Ingelheim (BI) today announced a strategic collaboration and licensing agreement with...
Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group...
German pharmaceutical giant Boehringer Ingelheim (BI) this week announced a licensing agreement with Denmark-based dermatology...
German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to...
Germany-based Boehringer Ingelheim and France-based Echosens have expanded their partnership to enhance early screening, precise...